Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides.
antisense oligonucleotide
biomarker
cerebrospinal fluid
dynamic light scattering
isothermal titration calorimetry
neurodegeneration
nuclear magnetic resonance
prion
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
18 12 2019
18 12 2019
Historique:
received:
18
11
2019
revised:
12
12
2019
accepted:
13
12
2019
entrez:
22
12
2019
pubmed:
22
12
2019
medline:
15
9
2020
Statut:
epublish
Résumé
Antisense oligonucleotides (ASOs) designed to lower prion protein (PrP) expression in the brain through RNase H1-mediated degradation of PrP RNA are in development as prion disease therapeutics. ASOs were previously reported to sequence-independently interact with PrP and inhibit prion accumulation in cell culture, yet
Identifiants
pubmed: 31861275
pii: biom10010001
doi: 10.3390/biom10010001
pmc: PMC7022474
pii:
doi:
Substances chimiques
Oligonucleotides, Antisense
0
Prion Proteins
0
Recombinant Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : F31 AI122592
Pays : United States
Déclaration de conflit d'intérêts
HTZ and HBK are employees and shareholders of Ionis Pharmaceuticals. EVM and SV have received research support in the form of charitable contributions from Ionis Pharmaceuticals and Charles River Laboratories. SV has received speaking fees from Illumina. EVM has consulted for Deerfield Management and Guidepoint. SLS serves on the Board of Directors of the Genomics Institute of the Novartis Research Foundation (“GNF”); is a shareholder and serves on the Board of Directors of Jnana Therapeutics; is a shareholder of Forma Therapeutics; is a shareholder and advises Decibel Therapeutics and Eikonizo Therapeutics; serves on the Scientific Advisory Boards of Eisai Co., Ltd., Ono Pharma Foundation, Exo Therapeutics, and F-Prime Capital Partners; and is a Novartis Faculty Scholar.
Références
J Med Chem. 2010 Apr 8;53(7):2719-40
pubmed: 20131845
Adv Drug Deliv Rev. 2015 Jun 29;87:46-51
pubmed: 25666165
J Biol Chem. 2001 Dec 28;276(52):49400-9
pubmed: 11604397
J Virol. 2003 Oct;77(19):10288-94
pubmed: 12970413
J Virol. 2003 May;77(9):5499-502
pubmed: 12692251
J Biol Chem. 2007 Apr 6;282(14):10153-63
pubmed: 17276992
Nature. 2014 Sep 25;513(7519):481-3
pubmed: 25254460
J Gen Virol. 2008 Feb;89(Pt 2):594-597
pubmed: 18198391
Mol Cell. 2018 Nov 1;72(3):426-443.e12
pubmed: 30401430
Antimicrob Agents Chemother. 2006 Mar;50(3):1034-44
pubmed: 16495266
Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7793-7798
pubmed: 30936307
Methods Mol Biol. 2017;1658:185-203
pubmed: 28861791
J Nat Prod. 2016 Mar 25;79(3):616-28
pubmed: 26900761
BMC Med. 2020 Jun 18;18(1):140
pubmed: 32552681
Int J Mol Sci. 2017 May 17;18(5):
pubmed: 28513534
Biochemistry. 2006 Aug 1;45(30):9180-7
pubmed: 16866364
Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12366-71
pubmed: 9356455
Mol Med. 2007 Mar-Apr;13(3-4):190-8
pubmed: 17592554
J Biol Chem. 2008 Jul 11;283(28):19616-25
pubmed: 18456654
J Med Chem. 2002 Apr 11;45(8):1712-22
pubmed: 11931626
Mol Ther Nucleic Acids. 2012 Feb 07;1:e9
pubmed: 23344724
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13363-83
pubmed: 9811807
J Pharmacol Exp Ther. 2001 Mar;296(3):890-7
pubmed: 11181921
J Biol Chem. 2004 Apr 23;279(17):17181-9
pubmed: 14960586
N Engl J Med. 2019 Jun 13;380(24):2307-2316
pubmed: 31059641
J Cell Physiol. 1993 Nov;157(2):319-25
pubmed: 7901226
J Pharmacol Exp Ther. 2014 Jul;350(1):46-55
pubmed: 24784568
Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:81-105
pubmed: 27732800
J Virol. 1993 Feb;67(2):643-50
pubmed: 7678300
Nucleic Acids Res. 2007;35(2):687-700
pubmed: 17182632
Biochemistry. 2012 Jul 10;51(27):5402-13
pubmed: 22691027
J Gen Virol. 2004 Aug;85(Pt 8):2479-2483
pubmed: 15269390
PLoS One. 2015 Dec 30;10(12):e0146021
pubmed: 26717316
Neurology. 2016 Mar 8;86(10):890-7
pubmed: 26865511
J Virol. 1988 May;62(5):1558-64
pubmed: 3282080
PLoS One. 2014 Sep 10;9(9):e107434
pubmed: 25207939
Mol Pharmacol. 2007 Jan;71(1):83-91
pubmed: 17028158
Nucleic Acids Res. 2016 Jun 20;44(11):5299-312
pubmed: 27131367
JCI Insight. 2019 Jul 30;5:
pubmed: 31361599
Mol Cell Proteomics. 2019 Dec;18(12):2388-2400
pubmed: 31558565
FASEB J. 2020 Jan;34(1):365-385
pubmed: 31914616
Nat Biotechnol. 2017 Mar;35(3):230-237
pubmed: 28244996